Skip to main content Back to Top
Advertisement

5/4/2020

Chlorothiazide Sodium Injection

Products Affected - Description

    • Sodium Diuril injection, Akorn, 500 mg, vial, 1 count, NDC 76478-0711-40
    • Chlorothiazide injection, Akorn, 500 mg, vial, 1 count, NDC 17478-0419-40
    • Chlorothiazide injection, Sagent, 500 mg, vial, 1 count, NDC 25021-0305-20

Reason for the Shortage

    • Akorn has chlorothiazide on allocation due to increased demand.
    • American Regent did not provide a reason for the shortage.
    • Fresenius Kabi did not provide a reason for the shortage.
    • Sagent has chlorothiazide injection on shortage due to manufacturing delays.
    • Sun Pharma is not marketing chlorothiazide injection.

Available Products

    • Chlorothiazide injection, American Regent, 500 mg, vial, 1 count, NDC 00517-1820-01
    • Chlorothiazide injection, Fresenius Kabi, 500 mg, vial, 1 count, NDC 63323-0658-20
    • Chlorothiazide injection, Mylan Institutional, 500 mg, vial, 1 count, NDC 67457-0263-30

Estimated Resupply Dates

    • Akorn has chlorothiazide 500 mg vials and Diuril 500 mg vials on allocation.
    • Sagent has chlorothiazide 500 mg vials on back order and the company estimates a release date of May 2020.

Updated

Updated May 4, 2020 by Michelle Wheeler, PharmD, Drug Information Specialist. Created March 6, 2020 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2020, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins


ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.